Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Conditions

• Recurrent Glioblastoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Bevacizumab — BIOLOGICAL
  Given IV
• Cediranib — DRUG
  Given PO
• Cediranib Maleate — DRUG
  Given PO
• Olaparib — DRUG
  Given PO

Study Details

This randomized phase II trial studies how well cediranib maleate and olaparib work compared to bevacizumab in treating patients with glioblastoma that has come back (recurrent). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Key Dates

Start date

Dec 7, 2017

Status verified

Jul 2025

Primary completion

Dec 31, 2022

Completion

Jul 17, 2026

Study Design

Enrollment

70 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Arm A (olaparib, cediranib maleate)
  Patients receive olaparib PO BID and cediranib maleate PO once QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
• Experimental: Arm B (bevacizumab)
  Patients receive bevacizumab IV over 30-90 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Number of Participants With Progression-Free Survival at 6 Months [ Time Frame: 6 months ]

Locations (27)

Find similar trials in La Jolla, CA

Related Studies

• Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
  PHASE1 · Recruiting · Sabine Mueller, MD, PhD · Birmingham, Alabama
• Sacituzumab Govitecan in Recurrent Glioblastoma
  PHASE2 · Recruiting · The University of Texas Health Science Center at San Antonio · Cleveland, Ohio
• BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma
  PHASE1 · Not Yet Recruiting · Mustafa Khasraw, MBChB, MD, FRCP, FRACP · Durham, North Carolina
• Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
  Recruiting · University of Miami · Miami, Florida